Low-risk localized prostate cancer: Are we ready to tell patients that active surveillance is the preferred option?

BJU International

Volumn 102, Issue 8, 2008, Pages 923-926

  Brewster, Simon F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SCREENING; DISEASE COURSE; HUMAN; MORTALITY; NOMOGRAM; NOTE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PSYCHOANALYSIS; QUALITY OF LIFE; RISK FACTOR; THERAPY DELAY;

HUMANS; MALE; PATIENT SATISFACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 52649121419     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07848.x     Document Type: Note

References (29)

1. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 101
2. Lu-Yao GL, Yao S-L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997 349 : 906 10
3. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
4. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM 2005 352 : 1977 84
5. Parker C, Muston D, Melia J et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 94 : 1361 8
6. Klotz L. Active surveillance with selective delayed intervention for favourable risk prostate cancer. Urol Oncol Semin Orig Invest 2006 24 : 46 50
7. Carter HB, Kettermann A, Warlick C et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007 178 : 2359 65
8. Soloway MS, Soloway CT, Williams S et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJUI 2008 101 : 165 9
9. Van As NJ, Parker CC. Active surveillance with selective radical treatment for localised prostate cancer. Cancer J 2007 13 : 289 94
10. Khatami A, Aus G, Damber J-E et al. PSA doubling time predicts the outcome after active surveillance in screen-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2006 120 : 170 4
11. Kattan MW, Eastham JA, Wheeler TM et al. Counselling men with prostate cancer: a nomogram for predicting the presence of small, moderately- differentiated, confined tumours. J Urol 2003 170 : 1792 1797
12. Steyerberg EW, Roobol MJ, Kattan MW et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007 177 : 107 12
13. Schröder FH, Carter HB, Wolters T et al. Early detection of prostate cancer in 2007. Part 1. PSA and PSA Kinetics. Eur Urol 2008 53 : 468 77
14. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of PSA density. J Urol 2003 170 : 370 2
15. Boccon-Gibod LM, Dumonceau O, Toublanc M et al. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005 48 : 895 9
16. Tsang WC, Kaur J, Roberts I, Brewster SF. Single focus prostate cancer on TRUS biopsy - does size matter? Eur Urol Supp 2008 7 : 274
17. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer volume: implication in selecting candidates for active surveillance. J Urol 2008 179 : 1804 10
18. Warlick C, Trock B, Landis P et al. Delayed versus immediate surgical intervention and prostate cancer outcome. JNCI 2006 98 : 355 7
19. D'Amico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. NEJM 2004 351 : 125 35
20. Benson MC, Whang IS, Olsson CA et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992 147 : 817 21
21. Venkitaraman R, Norman A, Woode-Amissah R et al. Prostate-specific antigen velocity in untreated localised prostate cancer. BJU Int 2007 101 : 161 4
22. Hoffman RM, Hunt WC, Gilliland FD et al. Patient satisfaction with treatment decisions for clinically localised prostate cancer. Results from the Prostate Cancer Outcomes Study. Cancer 2003 97 : 1653 62
23. Burnett KL, Parker C, Dearnaley D et al. Does active surveillance for men with localised prostate cancer carry psychological morbidity? BJU Int 2007 100 : 540 3
24. Pickles T, Dean Ruether J, Weir L et al. Psychological barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJUI 2007 100 : 544 51
25. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 58: Prostate Cancer; Diagnosis and Treatment. Available at: http://www.nice.org.uk/CG058. London : February 2008
26. Wilt TJ. Commentary: controversies in NICE guidance on prostate cancer. BMJ 2008 336 : 612 4
27. Phase III Randomized Study of Active Surveillance Versus Radical Treatment in Patients with Favorable-Risk Prostate Cancer. Available at: http://www.cancer.gov/clinicaltrials/CAN-NCIC-CTG-PR11
28. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomised trial comparing radical prostatectomy versus expectant management for the treatment of clinically-localised prostate cancer. J Urol 1994 152 : 1910 4
29. Donovan JL, Hamdy FC, Neal D et al. Prostate Testing for Cancer and Treatment (ProTecT) feasibility study. Health Technol Assess 2003 7 : 1 88